Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

Novartis and Ionis Pharmaceuticals reported that pelacarsen, a drug targeting lipoprotein(a) to reduce cardiovascular risk, failed to protect heart health in a large clinical trial, raising questions about the effectiveness of this emerging class of heart medicines.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.